Anti-C1q as Lupus Nephritis Marker
Keywords:
anti-C1q, anti-dsdna, lupus nephritis, systemic lupus erythematosus.Abstract
Introducción: Anti-C1q autoantibodies have been proposed as useful marker in systemic lupus erythematosus due to their association with lupus nephritis.
Objective: To determine the prevalence of anti-C1q in patients with systemic lupus erythematosus and other rheumatic diseases to evaluate the association with lupus nephropathy.
Methods: One hundred seventy-nine patients with systemic lupus erythematosus and 82 with other rheumatic diseases were included. Lupus nephritis was diagnosed in 70 (39%) of patients with systemic lupus erythematosus. Anti-C1q IgG antibodies were determined by ELISA. Associations were evaluated by logistic regression analysis.
Results: The prevalence of anti-C1q was 37% (66/179) in patients with systemic lupus erythematosus and 9% (7/82) in controls (OR = 6.3; 95% CI 2.8-14). .1; p < 0.001). Anti-C1q was associated with proteinuria (OR = 2.6; 95% CI 1.2-6.0; p < 0.022); elevated erythrocyte sedimentation rate (OR = 3.2; 95% CI 1.5-6.7; p < 0.003) and anti-dsDNA (OR = 3.9; 95% CI 1.7-9.1; p < 0.002). In the logistic regression model adjusted for demographics and anti-dsDNA, although the OR of anti-C1q for nephritis was 2-fold higher than in the absence of anti-C1q, it only approached statistical significance. Simultaneous positivity of anti-C1q and anti-dsDNA was associated with lupus nephritis (OR = 4.3; 95% CI 1.9-9.5; p < 0.001).
Conclusions: Anti-C1q occurred more frequently in patients with systemic lupus erythematosus than in controls. Anti-C1q combined with anti-dsDNA was strongly associated with lupus nephritis.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
The Cuban Journal of Medicine protects the author's patrimonial rights. However, it is licensed under a Creative Commons Licensehttps://creativecommons.org/licenses/by-nc/4.0/deed.es_ES which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided that the primary source of publication is duly cited. The author always retains his moral rights.
You are free to:
- Share - copy and redistribute the material in any medium or format.
- Adapt - remix, transform and build upon the material
- The license cannot revoke these freedoms as long as you follow the terms of the license.
Under the following terms:
- Attribution - You must give proper credit, provide a link to the license, and indicate if changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is supported by the licensor.
- Non-Commercial Purpose- You may not make use of the material for commercial purposes.
- No Additional Restrictions - You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.
